ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

National Drug Shortage Hits ENT Surgeries: Succinylcholine, propofol and tetracaine in limited supply

by Gina Shaw • April 27, 2011

  • Tweet
  • Email
Print-Friendly Version

Propofol is back in most pharmacy cabinets now, but the situation is far from ideal. The shortage originally began because two of the three U.S. manufacturers of the drug had problems in their plants, one related to sterility and the other having to do with metal particles in the compound. The U.S. Food and Drug Administration (FDA) ultimately cleared both manufacturers to restart propofol production, but one elected not to.

You Might Also Like

  • Drug Shortages in Otolaryngology
  • Rising Drug Costs Create Concern About Drug Diversions
  • Drug Selection Influences Drug-Induced Sleep Endoscopy Findings
  • Drug-Eluting Sinus Stent Hits the Market: May help maintain patency after FESS
Explore This Issue
May 2011

“So the supply was significantly impaired—right at the time of the worst of the economy—and it never really came back,” said Mauricio Gonzalez, MD, assistant professor of anesthesiology at Boston Medical Center. “The FDA issued an emergency dispensation that allowed us to get propofol from Europe, and a large amount of the supply is now coming from there. The problem is that all manufacturers have different preparations in terms of their inactive ingredients and the media used for suspension of the drug, and you really don’t know which brand you’ll have from week to week.”

Another drug popular for certain otolaryngology procedures recently disappeared from the market altogether. Production of tetracaine, known by the brand name Pontocaine, was discontinued in mid-2010 by its sole manufacturer, Hospira.

“This was a long-acting topical anesthetic agent that was very useful for office-based laryngeal procedures,” said Gregory Grillone, MD, associate professor and vice chair of the department of otolaryngology-head and neck surgery at Boston Medical Center. “I used topical Pontocaine for anesthetizing the surface of the larynx and the surrounding areas during procedures such as flexible endoscopy and lasering of a polyp or lesion, or for a biopsy. It was a much better topical anesthetic than the conventional varieties we are now forced to use, such as lidocaine and novocaine, which are not quite as potent or as long-lasting.”

Side Effects

The implications of ongoing drug shortages can be far more severe than just frustration or inconvenience. Switching from one drug to another usually means an entirely different dosage and side effect profile, which leaves the door open to medical errors. According to a survey done by the ISMP last fall, in at least six cases, patients have died because of mix-ups and dosing errors related to medication shortages. Even when the outcomes haven’t been so dire, a number of patients have experienced adverse events, ranging from respiratory problems to blood clots to hemorrhage.

“We had a very limited supply of morphine last year, which we use frequently with ENT patients,” Dr. Gonzalez said. “So we had to substitute hydromorphone, which is seven to 10 times more potent. That’s very risky when you’re not used to the dosage. Every time we have a shortage and have to change the way we practice, it’s not just forcing us to choose a drug that might be more costly or not do the job quite as well, but it’s also opening the door for accidents.”

Pages: 1 2 3 4 | Single Page

Filed Under: Everyday Ethics, Head and Neck, Practice Management Tagged With: drugs, Food and Drug Administration, head and neck cancerIssue: May 2011

You Might Also Like:

  • Drug Shortages in Otolaryngology
  • Rising Drug Costs Create Concern About Drug Diversions
  • Drug Selection Influences Drug-Induced Sleep Endoscopy Findings
  • Drug-Eluting Sinus Stent Hits the Market: May help maintain patency after FESS

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.